The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Open accessAbstract
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD. METHODS: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). Patients received 6 infusions, 13 weeks apart, with final assessments at week 78. The prespecified primary efficacy analysis in the modified intent-to-treat population assumed linear decline and compared treatment differences within dose cohorts on the Alzheimer's Disease Assessment Scale-Cognitive and Disability Assessment for Dementia. Exploratory analyses combined dose cohorts and did not assume a specific pattern of decline. RESULTS: No significant differences were found in the primary efficacy analysis. Exploratory analyses showed potential treatment differences (p < 0.05, unadjusted for multiple comparisons) on cognitive and functional endpoints in study "completers" and APOE epsilon4 noncarriers. Reversible vasogenic edema, detected on brain MRI in 12/124 (9.7%) bapineuzumab-treated patients, was more frequent in higher dose groups and APOE epsilon4 carriers. Six vasogenic edema patients were asymptomatic; 6 experienced transient symptoms. CONCLUSIONS: Primary efficacy outcomes in this phase 2 trial were not significant. Potential treatment differences in the exploratory analyses support further investigation of bapineuzumab in phase 3 with special attention to APOE epsilon4 carrier status. CLASSIFICATION OF EVIDENCE: Due to varying doses and a lack of statistical precision, this Class II ascending dose trial provides insufficient evidence to support or refute a benefit of bapineuzumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Frequency of ARIA events and in particular ARIA-E was significantly higher among APOE ε4 allele carriers compared to non-carriers, making the APOE ε4 allele a risk factor for vascular complications of anti-Aβ immunotherapy [5, 8, 14, 15].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Frequency of ARIA events and in particular ARIA-E was significantly higher among APOE ε4 allele carriers compared to non-carriers, making the APOE ε4 allele a risk factor for vascular complications of anti-Aβ immunotherapy [5, 8, 14, 15].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The greater incidence of these abnormalities with increasing bapineuzumab dose and number of APOEε4 alleles is consistent with phase 2 findings.11,13”
From Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease (2014) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Although clinical trials of the Aβ-directed mAb Bapinezumab showed no clear cognitive benefits in patients with mild to moderate AD [42], the results also indicated that APOE ε4 carrier status may limit the response to anti-Aβ passive immunization [43,44], as well as being associated with an increased rate of microbleeds and vasogenic edema [45].”
From Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice (2014) · cites this paper as [44]
In the citing paper
“in phase II trials, the anti-Aβ antibody bapineuzumab reduced CSF phospho-tau levels in patients with AD182,183”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [183]
In the citing paper
“In fact, there have been hints of some beneficial effects (clinical and biochemical) linked to human anti-Aβ immunotherapies (74-79).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Self-citationNeuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
Self-citation
Cited by
Sorted by citations
Items 201–300 of 752
Scholtzova, H., Chianchiano, P. E., Pan, J., Sun, Y., Goñi, F., Mehta, P. D., & Wısnıewskı, T. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0101-2 · Cited by 84
Small-molecule BACE1 inhibitors: a patent literature review (2006 – 2011)
Probst, G. D., & Xu, Y. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.681302 · Cited by 76
Shin, J., Lee, S., Kim, S. J., Kim, S., Cho, S., & Kim, Y.-B. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.04.013 · Cited by 76
Parasrampuria, D. A., Benet, L. Z., & Sharma, A. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0204-y · Cited by 80
Hampel, H. J., Schneider, L. S., Giacobini, E., Kivipelto, M., Sindi, S., Dubois, B., Broich, K., Nisticò, R., Aisen, P. S. S., & Lista, S. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995637 · Cited by 82
Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future
Prins, N. D., & Scheltens, P. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt220 · Cited by 79
Panza, F., Solfrizzi, V., Imbimbo, B. P., & Logroscino, G. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.935332 · Cited by 80
Clark, I. A., Atwood, C., Bowen, R. L., Paz-Filho, G., & Vissel, B. (2012) · Pharmacological Reviews · doi:10.1124/pr.112.005850 · Cited by 76
Current pharmacotherapy and putative disease-modifying therapy for Alzheimer’s disease
Kulshreshtha, A., & Piplani, P. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2625-7 · Cited by 76
Phase II clinical trials of anti–amyloid β antibodies: When is enough, enough?
Gold, M. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.04.005 · Cited by 75
La Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
Webster, L., Groskreutz, D., Grinbergs‐Saull, A., Howard, R. J., O'Brien, J. T., Mountain, G. A., Banerjee, S., Woods, B. T., Perneczky, R., Lafortune, L., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21260 · Cited by 75
Vasilevko, V., Passos, G. F., Quiring, D., Head, E., Kim, R. C., Fisher, M., & Cribbs, D. H. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05786.x · Cited by 74
Irwin, R. W., Solinsky, C. M., & Brinton, R. D. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00203 · Cited by 76
Rygiel, K. (2016) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.194867 · Cited by 76
Aβ immunotherapy for Alzheimer’s disease: effects on apoE and cerebral vasculopathy
Sakai, K., Boche, D., Carare, R., Johnston, D., Holmes, C., Love, S., & Nicoll, J. A. R. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1340-9 · Cited by 72
Hasegawa, M. (2016) · Biomolecules · doi:10.3390/biom6020024 · Cited by 75
Rabins, P. V., Rovner, B. W., Rummans, T. A., Schneider, L. S. S., & Tariot, P. N. (2017) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.15106 · Cited by 77
Gadhave, K., Kumar, D., Uversky, V. N., & Giri, R. (2020) · Medicinal Research Reviews · doi:10.1002/med.21719 · Cited by 71
Engineering antibody and protein therapeutics to cross the blood–brain barrier
Zhao, P., Zhang, N., & An, Z. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac028 · Cited by 75
Dementia: Alzheimer pathology and vascular factors: From mutually exclusive to interaction
van Norden, A. G. W., van Dijk, E. J., de Laat, K. F., Scheltens, P., Olde-Rikkert, M. G. M., & de Leeuw, F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.07.003 · Cited by 75
Penninkilampi, R., Brothers, H. M., & Eslick, G. D. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9722-5 · Cited by 71
Antibodies and protein misfolding: From structural research tools to therapeutic strategies
Genst, E. D., Messer, A. C., & Dobson, C. M. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.08.016 · Cited by 70
You, M., Pan, Y., Liu, Y., Chen, Y., Wu, Y., Si, J., Wang, K., & Hu, F. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00428 · Cited by 70
(2013) · PubMed · Cited by 66
Kariv-Inbal, Z., Yacobson, S., Berkecz, R., Péter, M., Janáky, T., Lütjohann, D., Broersen, L. M., Hartmann, T., & Michaelson, D. M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111265 · Cited by 70
Takamatsu, K., Ikeda, T., Haruta, M., Matsumura, K., Ogi, Y., Nakagata, N., Uchino, M., Ando, Y., Nishimura, Y., & Senju, S. (2014) · Stem Cell Research · doi:10.1016/j.scr.2014.10.001 · Cited by 69
Arrighi, H. M., Barakos, J. A., Barkhof, F., Tampieri, D. I., Jack, C. R., Melançon, D., Morris, K., Ketter, N., Liu, E., & Brashear, H. R. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309493 · Cited by 71
Self-citationAmyloid and Alzheimer's Disease: Inside and Out
Tam, J. H. K., & Pasternak, S. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013408 · Cited by 64
Amyloid‐related imaging abnormalities from trials of solanezumab for Alzheimer's disease
Carlson, C. D., Siemers, E., Hake, A. M., Case, M. G., Hayduk, R., Suhy, J., Oh, J., & Barakos, J. A. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.02.004 · Cited by 67
Self-citationPrion-like mechanisms and potential therapeutic targets in neurodegenerative disorders
Hasegawa, M., Nonaka, T., & Masuda‐Suzukake, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.010 · Cited by 71
Brain delivery of biologics using a cross‐species reactive transferrin receptor 1 VNAR shuttle
Sehlin, D., Stocki, P., Gustavsson, T., Hultqvist, G., Walsh, F. S., Rutkowski, J. L., & Syvänen, S. (2020) · The FASEB Journal · doi:10.1096/fj.202000610rr · Cited by 64
Hull, M., Sadowsky, C., Arai, H., Leterme, G. L. P., Holstein, A., Booth, K., Peng, Y., Yoshiyama, T., Suzuki, H., Ketter, N., et al. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170117101537 · Cited by 65
Self-citationAlzheimer’s disease: biological aspects, therapeutic perspectives and diagnostic tools
Carlo, M. D., Giacomazza, D., & Biagio, P. L. S. (2012) · Journal of Physics Condensed Matter · doi:10.1088/0953-8984/24/24/244102 · Cited by 67
Campolo, M., Esposito, E., Ahmad, A., Paola, R. D., Paterniti, I., Cordaro, M., Bruschetta, G., Wallace, J. L., & Cuzzocrea, S. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0196-1 · Cited by 64
Perispinal etanercept: a new therapeutic paradigm in neurology
Tobinick, E. L. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.52 · Cited by 64
Inflammatory Markers in Mild Cognitive Impairment: A Meta-Analysis
Saleem, M., Herrmann, N., Swardfager, W., Eisen, R. B., & Lanctôt, K. L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150042 · Cited by 64
The dark sides of amyloid in Alzheimer's disease pathogenesis
Sorrentino, P., Iuliano, A., Polverino, A., Jacini, F., & Sorrentino, G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2013.12.038 · Cited by 64
Amyloid-beta immunotherapy: the hope for Alzheimer disease?
Barrera-Ocampo, A. A., & Lopera, F. J. (2016) · Colombia medica · doi:10.25100/cm.v47i4.2640 · Cited by 64
Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease
Haas, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110986 · Cited by 61
Bachmeier, C. J., Beaulieu‐Abdelahad, D., MULLAN, M. J., & Paris, D. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.03.048 · Cited by 64
Imaging endpoints for clinical trials in Alzheimer’s disease
Cash, D. M., Rohrer, J. D., Ryan, N. S., Sebastien Ourselin, A., & Fox, N. C. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0087-9 · Cited by 62
Self-citationSalloway, S., Wojtowicz, J., Voyle, N., Lane, C., Klein, G., Lyons, M., Rossomanno, S., Mazzo, F., Bullain, S., Barkhof, F., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.3937 · Cited by 62
Self-citationZago, W., Schroeter, S., Guido, T., Khan, K., Seubert, P., Yednock, T., Schenk, D., Gregg, K. M., Games, D., Bard, F., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.010 · Cited by 75
Self-citationWalters, S., Contreras, A. G., Eissman, J. M., Mukherjee, S., Lee, M. L., Choi, S., Scollard, P., Trittschuh, E. H., Mez, J., Bush, W. S., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.2169 · Cited by 65
Lehmann, M., Ghosh, P., Madison, C. A., Karydas, A., Coppola, G., O’Neil, J. P., Huang, Y., Miller, B. L., Jagust, W., & Rabinovici, G. D. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305858 · Cited by 61
An MRI Rating Scale for Amyloid-Related Imaging Abnormalities with Edema or Effusion
Barkhof, F., Daams, M., Scheltens, P., Brashear, H. R., Arrighi, H. M., Bechten, A., Morris, K., McGovern, M., & Wattjes, M. P. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3475 · Cited by 60
Secondary prevention of Alzheimer’s dementia: neuroimaging contributions
ten Kate, M., Ingala, S., Schwarz, A. J., Fox, N. C., Chételat, G., van Berckel, B. N. M., Ewers, M., Foley, C., Gispert, J. D., Hill, D., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0438-z · Cited by 65
Self-citationRepeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation
Rozenstein-Tsalkovich, L., Grigoriadis, N., Lourbopoulos, A., Nousiopoulou, E., Kassis, I., Abramsky, O., Karussis, D., & Rosenmann, H. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.07.006 · Cited by 66
Bapineuzumab: Anti-β-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer‘s Disease
Panza, F., Frisardi, V., Imbimbo, B. P., D’Onofrio, G., Pietrarossa, G., Seripa, D., Pilotto, A., & Solfrizzi, V. (2010) · Immunotherapy · doi:10.2217/imt.10.80 · Cited by 59
New treatment strategies for Alzheimer's disease: is there a hope?
Aprahamian, I., Stella, F., & Forlenza, O. V. (2013) · Europe PMC (PubMed Central) · Cited by 59
Developing therapeutic vaccines against Alzheimer’s disease
Wısnıewskı, T., & Drummond, E. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1121815 · Cited by 60
Delnomdedieu, M., Duvvuri, S., Li, D. J., Atassi, N., Lu, M., Brashear, H. R., Liu, E., Ness, S. L., & Kupiec, J. W. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0177-y · Cited by 61
Self-citationIntegrating ADNI results into Alzheimer's disease drug development programs
Cummings, J. L. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.016 · Cited by 59
Alzheimer’s-Related Peptide Amyloid-β Plays a Conserved Role in Angiogenesis
Cameron, D. J., Galvin, C. J., Alkam, T., Sidhu, H., Ellison, J., Luna, S., & Ethell, D. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039598 · Cited by 59
Vitamin E and memantine in Alzheimer's disease: Clinical trial methods and baseline data
Dysken, M. W., Guarino, P., Vertrees, J. E., Asthana, S., Sano, M. C., Llorente, M. D., Pallaki, M., Love, S. B., Schellenberg, G. D., McCarten, J. R., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.014 · Cited by 62
Antibody-based therapy in Alzheimer's disease
Pul, R., Dodel, R. C., & Stangel, M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.552884 · Cited by 59
Pankiewicz, J. E., Guridi, M., Kim, J., Asuni, A. A., Sanchez, S., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0075-0 · Cited by 57
Wilcock, D. M., Morgan, D., Gordon, M. N., Taylor, T. L., Ridnour, L. A., Wink, D. A., & Colton, C. A. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-115 · Cited by 58
New and emerging treatments for Alzheimer’s disease
Corbett, A., Smith, J. S., & Ballard, C. G. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.43 · Cited by 58
Lindström, V., Ihse, E., Fagerqvist, T., Bergström, J. J. E., Nordström, E. K. L., Möller, C., Lannfelt, L., & Ingelsson, M. (2014) · Immunotherapy · doi:10.2217/imt.13.162 · Cited by 56
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
Krafft, G. A., Jerecı̀ć, J., Siemers, E., & Cline, E. N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.848215 · Cited by 54
Burstein, A. H., Zhao, Q., Ross, J., Styren, S. D., Landen, J. W., Ma, W. W., McCush, F., Alvey, C. W., Kupiec, J. W., & Bednar, M. M. (2013) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318279bcfa · Cited by 53
Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease
Panza, F., Solfrizzi, V., Imbimbo, B. P., Giannini, M., Santamato, A., Seripa, D., & Logroscino, G. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.945522 · Cited by 51
Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer’s Disease
Novak, G., Fox, N. C., Clegg, S., Nielsen, C. F., Einstein, S. G., Lü, Y., Tudor, I. C., Gregg, K. M., Di, J., Collins, P. V., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150448 · Cited by 54
Self-citationNature and Nurture of Catalytic Antibodies
Paul, S., Planque, S. A., Nishiyama, Y., Hanson, C. V., & Massey, R. J. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3461-0_5 · Cited by 53
Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before
Mancuso, C., Siciliano, R., Barone, E., Butterfield, D. A., & Preziosi, P. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.601740 · Cited by 53
Moghbel, M. C., Saboury, B., Basu, S. K., Metzler, S. D., Torigian, D. A., Långström, B., & Alavi, A. A. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1960-4 · Cited by 53
Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases
Katsuno, M., Tanaka, F., & Sobue, G. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301307 · Cited by 52
Feinberg, H., Saldanha, J. W., Diep, L., Goel, A. S., Widom, A., Veldman, G. M., Weis, W. I., Schenk, D., & Basi, G. S. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt261 · Cited by 52
Self-citationCerebral amyloid angiopathy and related inflammatory disorders
Chwalisz, B. K. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117425 · Cited by 53
Zhang, X., Imel, E. A., Ruppe, M. D., Weber, T. J., Klausner, M. A., Ito, T., Vergeire, M., Humphrey, J. S., Glorieux, F. H., Portale, A. A., et al. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.570 · Cited by 51
Antibody Therapeutics Targeting Aβ and TauPreprint
Gallardo, G., & Holtzman, D. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024331 · Cited by 55
Curcumin: a natural substance with potential efficacy in Alzheimer’s disease
Potter, P. E. (2013) · Journal of Experimental Pharmacology · doi:10.2147/jep.s26803 · Cited by 51
Apolipoprotein E Isoform-Specific Effects on Lipoprotein Receptor Processing
Bachmeier, C. J., Shackleton, B., Ojo, J. O., Paris, D., MULLAN, M. J., & Crawford, F. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-014-8318-6 · Cited by 50
Alzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug Development
Savonenko, A. V., Melnikova, T., Hiatt, A., Li, T., Worley, P. F., Troncoso, J. C., Wong, P. C., & Price, D. L. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.211 · Cited by 52
Global gray matter changes in posterior cortical atrophy: A serial imaging study
Lehmann, M., Barnes, J., Ridgway, G. R., Ryan, N. S., Warrington, E. K., Crutch, S. J., & Fox, N. C. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.09.225 · Cited by 49
Self-citationApolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease
Kline, A. D. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt135 · Cited by 53
Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges
Cynis, H., Frost, J. L., Crehan, H., & Lemere, C. A. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0115-2 · Cited by 49
Future Therapeutics in Alzheimer’s Disease: Development Status of BACE Inhibitors
Evin, G. M. (2016) · BioDrugs · doi:10.1007/s40259-016-0168-3 · Cited by 52
Tohda, C., Nakada, R., Urano, T., Okonogi, A., & Kuboyama, T. (2011) · International Journal of Neuroscience · doi:10.3109/00207454.2011.602809 · Cited by 50
Solanezumab for Alzheimer's disease
Samadi, H., & Sultzer, D. L. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.578573 · Cited by 48
Amanatkar, H. R., Papagiannopoulos, B., & Grossberg, G. T. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1194203 · Cited by 47
Overview of therapeutic targets in management of dementia
Malik, R., Kalra, S., Bhatia, S., Al‐Harrasi, A., Singh, G., Mohan, S., Makeen, H. A., Albratty, M., Meraya, A. M., Bahar, B., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113168 · Cited by 51
Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease
Padhi, D., & Govindaraju, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00335 · Cited by 47
Madhu, P., & Mukhopadhyay, S. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30141 · Cited by 53
The advent of Alzheimer treatments will change the trajectory of human aging
Selkoe, D. J. (2024) · Nature Aging · doi:10.1038/s43587-024-00611-5 · Cited by 49
Pieper, M. J. C., Achterberg, W. P., Francke, A. L., van der Steen, J. T., Scherder, E., & Kovach, C. R. (2011) · BMC Geriatrics · doi:10.1186/1471-2318-11-12 · Cited by 47
Immunity and Alzheimer's disease: immunological perspectives on the development of novel therapies
Liu, Y.-H., Zeng, F., Wang, Y., Zhou, H., Giunta, B. N., Tan, J., & Wang, Y. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.020 · Cited by 48
Boncoraglio, G. B., Piazza, F., Savoiardo, M., Farina, L., DiFrancesco, J. C., Prioni, S., Tagliavini, F., Parati, E. A., & Giaccone, G. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142376 · Cited by 45
IgG Fc N-glycosylation: Alterations in neurologic diseases and potential therapeutic target?
Kronimus, Y., Dodel, R. C., Galuska, S. P., & Neumann, S. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.006 · Cited by 48
Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain
Brimson, J. M., Brimson, S., Chomchoei, C., & Tencomnao, T. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1805435 · Cited by 46
Meilandt, W. J., Maloney, J. A., Imperio, J., Lalehzadeh, G., Earr, T., Crowell, S., Bainbridge, T. W., Lu, Y., Ernst, J. A., Fuji, R. N., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0553-5 · Cited by 45
A Longitudinal Study of Behavioral Deficits in an AβPP Transgenic Mouse Model of Alzheimer's Disease
Havas, D., Hutter‐Paier, B., Ubhi, K. K., Rockenstein, E. M., Crailsheim, K., Masliah, E., & Windisch, M. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101866 · Cited by 45
Bales, K. R. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.666234 · Cited by 46
Vellas, B. J., Hampel, H. J., Bugat, M.-È. R., Grundman, M., Andrieu, S., Abushakra, S. R., Bateman, R. J., Berman, R., Black, R. S., Carrillo, M. C., et al. (2012) · The journal of nutrition health & aging · doi:10.1007/s12603-012-0044-x · Cited by 45
Self-citationA Generic Method for Design of Oligomer-Specific Antibodies
Brännström, K., Lindhagen‐Persson, M., Gharibyan, A. L., Iakovleva, I., Vestling, M., Sellin, M. E., Brännström, T., Morozova‐Roche, L. A., Forsgren, L., & Olofsson, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090857 · Cited by 45
Conti, E., Gregori, M., Radice, I., Re, F. D., Grana, D., Re, F., Salvati, E., Masserini, M., Ferrarese, C., Zoia, C., et al. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.02.012 · Cited by 46
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab
Liu, E., Wang, D., Sperling, R. A., Salloway, S., Fox, N. C., Blennow, K., Scheltens, P., Schmidt, M. E., Streffer, J. R., Novak, G., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005060 · Cited by 42
Self-citationComparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies
Fuller, J. P., Stavenhagen, J. B., Christensen, S., Kartberg, F., Glennie, M. J., & Teeling, J. L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1484-2 · Cited by 46
Metadata
- Authors
- Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., Mulnard, R., Barakos, J., Gregg, K. M., Liu, E., Lieberburg, I., Schenk, D., Black, R., & Grundman, M.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Butler Hospital (S.S.), Providence, RI; Brigham & Women's Hospital (R.S.), Boston, MA; University of Michigan (S.G.), Ann Arbor; UCL (N.C.F.), Institute of Neurology, London, UK; University of Göteborg (K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; VA Medical Center (M.R.), Seattle, WA; Cleo Roberts Center for Clinical Research/Sun Health Research Institute (M.S.), Sun City, AZ; Columbia University (L.S.H.), New York, NY; Baylor College of Medicine (R.D.), Houston, TX; Yale...
- Venue
- Neurology
- Published
- 2009-12-15
- Volume
- 73
- Issue
- 24
- Pages
- 2061-2070
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC2790221
- OpenAlex
- W2086572083
- Cited by
- 753
- References
- 40
- Citations by year
- 2026: 18 · 2025: 20 · 2024: 25 · 2023: 21 · 2022: 34 · 2021: 21 · 2020: 30 · 2019: 30 · 2018: 26 · 2017: 30 · 2016: 45 · 2015: 52 · 2014: 71 · 2013: 78 · 2012: 91
- FWCI
- 55.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Pfizer
- National Institute for Health and Care Research (NF-SI-0508-10123)
- National Institutes of Health (5r03ag023916-02, 5r01ag007370-30, 1r41ns056856-01a2, 5u01ag024904-10)
- U.S. Public Health Service (UO1AGO24904)
- National Institute on Alcohol Abuse and Alcoholism (RL1AA017536)
- National Institute on Aging (U01-AG-024904, R01AG030457, R01AG14763, AG 08671, 1-R01-AG030457-01A1, P01AG007232, R01AG026114, U01AG016976, R01-AG007370, R43AG033474, U01AG010483, U01-AG 16976, 1-UO1-AG024904, 1 R03 AG023916-01A1, P01AG030004, P50AG008702, R01AG027435, R01AG017761, P01AG07232, P50AG008671, P30AG019610, P30 P3-AG 019610, P50AG005136, P50AG005134, U01AG032438, P50 AG08671, 5-U01-AG10483, AG06036-13, P50AG08702)
- National Heart, Lung, and Blood Institute (R01HL091099)
- National Institute of Mental Health (1 R01 MH58620-01A2, P50MH068789, R01MH058620)
- National Institute of Diabetes and Digestive and Kidney Diseases (IR21DK062098)
- National Institute of Neurological Disorders and Stroke (P01 NS 15655, P01NS015655, R01NS042859, T32NS007224)
- National Center for Research Resources (U54RR024350-01, P20RR020626)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- bapineuzumab, Alzheimer's disease, anti-amyloid beta monoclonal antibody, amyloid-beta, vasogenic edema, APOE ε4 carriers, cognitive decline, functional decline, dose escalation, treatment efficacy, drug safety
- MeSH terms
- Aged, Alzheimer Disease, Antibodies, Monoclonal, Brain, Brain Edema, Cognition, Dose-Response Relationship, Drug, Female, Heterozygote, Humans, Magnetic Resonance Imaging, Male, Severity of Illness Index, Biomarkers, Treatment Outcome, Apolipoprotein E4, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
